VivoSeq
Musculoskeletal

Temporomandibular Disorder

2

Pipeline Programs↗

3

Active Trials↗

1

Companies Involved↗

Temporomandibular Disorder is an early-stage landscape with 2 programs across 1 company. The most active players are sevilay seda bas.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

sevilay seda bas

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical2

Injectable Platelet-Rich Fibrin

Wroclaw Medical University

Platelet Rich Plasma

Zagazig University

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

6

clinical trials

Completed3 · 50%
Enrolling by invitation2 · 33%
Recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

An Investigation of Cranio-Cervico-Mandibular Factors Predicting the Severity of Temporomandibular Disorders
Recruiting·—·N/A·NCT07666360·60 enrolled
Assessment of the Effectiveness of Intra-articular Injectable Platelet-rich Fibrin (iPRF) Injections in the Management of Mild and Moderate Degeneration of the Temporomandibular Joints
Enrolling by invitation·WWroclaw Medical University·Preclinical·NCT05214924·42 enrolled
Determination of Chronic Pain, Anxiety, Depression and Perceived Stress in Adults With Temporomandibular Disorders
Enrolling by invitation·WWroclaw Medical University·N/A·NCT05183503·219 enrolled
Efficacy of a Standardized Centella Asiatica Extract in Patients With Temporomandibular Disorder
Completed·—·Phase 2/3·NCT06231212·23 enrolled
Evaluation of the Efficacy of Different Drugs in the Treatment of the Pain in Patients With Temporomandibular Disorder
Completed·YYuzuncu Yil University·Phase 4·NCT05529290·200 enrolled
Safety and Efficacy of Erenumab-aooe in Patients With Temporomandibular Disorder
Completed·IIndiana University·Phase 2·NCT04884763·30 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)